GlassScriptPhysician profile
Dennis Mccoy
NPI 1700818804
$7,082.43
in general payments reported to CMS, 2019-2025
24 companies · $2,032 in 2025
The $2,032 reported for 2025 was more than what 79% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $30.92 · 2021: $29.59 · 2022: $1,347 · 2023: $1,831 · 2024: $695 · 2025: $2,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,405 · Food and Beverage: $2,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,405.08 |
| Food and Beverage | $2,153.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,678.09 | 2019-2025 | Wavewriter Alpha Prime 16, Patient Trial Kit |
| Nevro Corp. | $1,326.80 | 2019-2023 | Senza |
| Si-Bone, INC. | $1,039.15 | 2024-2025 | |
| Medtronic, INC. | $819.54 | 2024-2025 | Intellis Adaptivestim, Synchromedii |
| Nalu Medical, INC. | $406.55 | 2022-2023 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $369.47 | 2022-2025 | Relistor |
| Abbvie INC. | $247.96 | 2022-2025 | |
| Protega Pharmaceutials INC | $239.36 | 2023-2024 | Roxybond |
| Grt US Holding, INC. | $228.68 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $126.54 | 2019-2024 | Xtampza, Belbuca |
| Biohaven Pharmaceutical Holding Company LTD. | $96.94 | 2022 | |
| Pfizer INC. | $67.20 | 2019-2023 | |
| Vertex Pharmaceuticals Incorporated | $67.17 | 2024-2025 | |
| Scilex Pharmaceuticals INC. | $54.55 | 2022-2023 | Ztlido |
| Averitas Pharma INC. | $45.66 | 2023-2024 | Qutenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $41.97 | 2019-2025 | Eterna |
| Stimwave Technologies Incorporated | $39.28 | 2022 | |
| Daiichi Sankyo INC. | $36.92 | 2019 | |
| Tersera Therapeutics LLC | $36.81 | 2022 | |
| Bioventus LLC | $28.13 | 2022 | |
| Mdd US Operations, LLC | $27.70 | 2019 | |
| Vertos Medical, INC. | $25.73 | 2023 | Mild Device Kit |
| Curonix LLC | $16.90 | 2022 | |
| Globus Medical, INC. | $15.33 | 2025 | Vyrsa V1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Mccoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.